ILKO Pharmaceuticals aims to introduce ‘innovative’ products that extend life and save lives and to add value to this industry by making a difference in pharmaceutical production. To this end, ILKO Pharmaceuticals operates in two R&D centers.
ILKO Research and Development Center (ILKO ARGEM), which was established in 2009 in Hacettepe University Technology Development Zone, has a closed area of 2,600 m². ILKO Argem is a pioneering and exemplary R&D investment based on university-industry collaboration within the Technology Development Zone in Turkey.
ILKO ARGEM consists of four main units: analytical, formulation, patent and clinical research. With the main focus of developing value added products as well as new therapeutic entities, specialty medicines and biopharmaceuticals, our highly qualified R&D scientist work in our laboratories equipped with advanced technology and infrastructure.
Innovative Technologies
ILKO Pharmaceuticals established the ILKO ARGEM Biotechnology R&D Center in Teknopark İstanbul in 2015 and continues its R&D studies on biotechnological products in this center. It is the first biotechnology R&D center in Turkey.
ILKO Argem Biotechnology Center, develops biopharmaceuticals using recombinant DNA technology and different expression systems. The biotechnology center includes separate departmens for upstream processing, downstream processing and quality control units owning high technology infrastructure. Research and development of biosimilars, biobetters, new generation drugs with new pharmaceutical targets forms the main the scope of the center. Our biotechnology projects are focused on Anti-Cancer and Anti-TNF drugs mainly.